Enhancing patient-specific quality assurance for VMAT for breast cancer treatment: A machine learning approach for gamma passing rate (GPR) prediction

提高乳腺癌VMAT治疗中患者个体化质量保证:基于机器学习的伽马通过率(GPR)预测方法

阅读:1

Abstract

BACKGROUND: Modern radiation therapy for breast cancer has significantly advanced with the adoption of volumetric modulated arc therapy (VMAT), offering enhanced precision and improved treatment efficiency. PURPOSE: To ensure the accuracy and precision of such complex treatments, a robust patient-specific quality assurance (PSQA) protocol is essential. This study investigates the potential of machine learning (ML) models to predict gamma passing rates (GPR), a key metric in PSQA. METHODS: A dataset comprising 863 VMAT plans was used to develop and compare seven ML models: Histogram-based gradient boosting regressor, random forest regressor, extra trees regressor, gradient boosting regressor, linear regression, AdaBoost regressor, and Multi-layer perceptron regressor. These models incorporated anatomical, dosimetric, and plan complexity features. RESULTS: Among the evaluated models, the extra trees regressor (ETR), random forest regressor (RFR), and gradient boosting regressor (GBR) demonstrated the best performance, achieving mean absolute errors (MAEs) of 0.51%, 0.52%, and 0.51%, and mean squared errors (MSEs) of 0.0051%, 0.0051%, and 0.0052%, respectively, on the validation dataset. CONCLUSIONS: This study highlights the promise of ML-based approaches in streamlining PSQA processes, thereby supporting the quality assurance of breast cancer treatments using VMAT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。